Pharmacology/Pharmaceutical Industry
‘Panic Prescribing’ Untested Coronavirus Treatments
1 Apr, 2020 | 05:51h | UTC- ‘Panic Prescribing’ Untested Coronavirus Treatments: A Danger To Patients Today and Tomorrow – Health Affairs
- We shouldn’t rush to use an unproven malaria drug to treat the coronavirus – STAT
- See also: Twitter Thread on the Latest Study Testing Hydroxychloroquine, by Lucas Morin
[Abstract Only] A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
1 Apr, 2020 | 05:39h | UTCA Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity – New England Journal of Medicine (link to abstract – $ for full-text)
COVID-19: Risks Related to the Use of Hydroxychloroquine
31 Mar, 2020 | 04:48h | UTC- Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 – American College of Cardiology
- A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 – Annals of Internal Medicine
[Preprint] COVID-19: Hydroxychloroquine Beneficial in Small Trial
31 Mar, 2020 | 04:51h | UTC
COVID-19 and Renin-Angiotensin System Blockers
30 Mar, 2020 | 02:00h | UTCRenin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers – Hypertension AND Commentary: COVID-19 alert: Heart and kidney patients should keep taking their medicines – University of Miami Miller School of Medicine
Related Guidelines: HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology AND The Renal Association, UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use AND Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers – European Society of Cardiology
#ACC20 – [Abstract only] Randomized Trial: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
30 Mar, 2020 | 01:20h | UTCRivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: PRONOMOS: Rivaroxaban Better Than Enoxaparin in Preventing VTE After Nonmajor Orthopedic Surgery – American College of Cardiology (free) AND PROphylaxis in NON-Major Orthopedic Surgery – PRONOMOS – American College of Cardiology (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
30 Mar, 2020 | 01:13h | UTCAnticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients With a Long-Term Indication for Oral Anticoagulation – POPular TAVI – American College of Cardiology (free)AND A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
30 Mar, 2020 | 01:18h | UTCVericiguat in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA – TCTMD (free) AND VICTORIA: Vericiguat Associated With Reduced CV Death, HF Hospitalization in High-Risk HF Patients – American College of Cardiology
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Randomized Trial: Rivaroxaban in Peripheral Artery Disease after Revascularization
30 Mar, 2020 | 01:05h | UTCRivaroxaban in Peripheral Artery Disease after Revascularization – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: VOYAGER-PAD: Rivaroxaban Associated With Reduced Adverse Limb, CV Events in PAD Patients – American College of Cardiology (free) AND VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events – TCTMD (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – Randomized Trial: Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
30 Mar, 2020 | 01:03h | UTCSee also: Visual Abstract
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
#ACC20 – [Abstract Only] Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
30 Mar, 2020 | 01:12h | UTCApixaban for the Treatment of Venous Thromboembolism Associated with Cancer – New England Journal of Medicine (abstract Only – $ for full-text)
Commentaries: Caravaggio Trial: Apixaban Noninferior to Dalteparin in Treatment of Cancer-Associated VTE – American College of Cardiology (free) AND Apixaban, Dalteprin Shown to Have Same Bleeding Risk in Patients With Cancer – AJMC (free)
Just Presented at the 2020 American College of Cardiology Virtual Meeting (free access)
BCCDC Position Statement on Unproven Therapies for COVID-19
27 Mar, 2020 | 03:48h | UTCRecommendation: Unproven Therapies for COVID-19 | March 24, 2020 – BC Centre for Disease Control
Randomized Trial: Aspirin Not Beneficial for Reducing the Risk of Dementia, MCI, or Cognitive Decline
26 Mar, 2020 | 02:20h | UTCCommentary: Study: An aspirin a day does not keep dementia at bay – American Academy of Neurology (free)
Hydroxychloroquine: Small Study Shows No Benefit
26 Mar, 2020 | 01:39h | UTCCommentary: Chloroquine Use For COVID-19 Shows No Benefit In First Small—But Limited—Controlled Trial – Forbes
Related: Coronavirus treatment hype can lead to harm – Lown Institute AND No, These Medicines Cannot Cure Coronavirus – The New York times
See also: Chloroquine for COVID-19: Cutting Through the Hype
Pill Splitting: Making the Most of Meds in a Time of Need
25 Mar, 2020 | 02:29h | UTC
Chloroquine for COVID-19: Cutting Through the Hype
24 Mar, 2020 | 11:32h | UTCChloroquine for COVID-19: Cutting Through the Hype – The Scientist
Review: Anti-arrhythmic Properties of Non-antiarrhythmic Medications
24 Mar, 2020 | 11:12h | UTCAnti-arrhythmic properties of non-antiarrhythmic medications – Pharmacological Research (free)
[Preprint] Randomized Trial: Favipiravir vs. Arbidol for COVID-19
23 Mar, 2020 | 01:18h | UTCFavipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial – medRxiv
New Preliminary Studies with Hydroxychloroquine:
20 Mar, 2020 | 10:57h | UTCThis was an open-label study with only 42 patients without patient-relevant endpoints. The 6 patients that received Hydroxychloroquine + Azithromycin achieved more efficient virus elimination than control patients.
New in Vitro Study: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro – Cell Discovery (free)
Related Articles: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – Clinical Infectious Diseases (free PDF) AND New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? – International Journal of Antimicrobial Agents (free) AND A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 – Journal of Critical Care (free) AND Of chloroquine and COVID-19 – Antiviral Research (free)
Consensus Guideline: Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus Aureus Infections
20 Mar, 2020 | 11:07h | UTC
FDA: Stop SGLT2 Inhibitors Before Scheduled Surgery
20 Mar, 2020 | 10:52h | UTCCommentary: FDA advises stopping SGLT2 inhibitor treatment prior to surgery – The Hospitalist (free)
“- Canagliflozin, dapagliflozin, and empagliflozin should each be discontinued at least three days before scheduled surgery.
– Ertugliflozin should be discontinued at least four days before scheduled surgery.
– Blood glucose levels should be carefully monitored after discontinuation of the SGLT2 inhibitor and appropriately managed before surgery.”
Randomized Trial: No Benefit from Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
19 Mar, 2020 | 11:01h | UTCEditorial: Covid-19 — The Search for Effective Therapy (free)
See also: Interview with Dr. Eric Rubin and Dr. Lindsey Baden on new research on possible treatments for Covid-19 – New England Journal of Medicine (free)
Perspective: Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
19 Mar, 2020 | 10:52h | UTCConfirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed? – JAMA (free for a limited period)
Original Article: Randomized Trial: Injectable 17-α-hydroxyprogesterone Not Effective for the Prevention of Recurrent Preterm Birth (free study and commentaries)
Related Study: A Randomized Trial of Progesterone in Women with Recurrent Miscarriages – New England Journal of Medicine (free)
Randomized, Phase 2 Trial: Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Children Aged 2–17 Years
18 Mar, 2020 | 09:47h | UTCSafety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)
[Abstract Only] Study: Consequences of Measles Undervaccination
18 Mar, 2020 | 09:49h | UTCConsequences of Undervaccination – Measles Outbreak, New York City, 2018-2019 – New England Journal of Medicine (link to abstract – $ for full-text)